Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’

This paper characterizes the successful civil lawsuits brought by sub-national units of government in the US against multinational pharmaceutical companies to recover the costs of public expenditures (goods and services) incurred as they attempt to manage the ‘opioid crisis,’ as a scapegoating strat...

Full description

Bibliographic Details
Main Author: Katherine Pettus
Format: Article
Language:English
Published: LSE Press 2020-08-01
Series:Journal of Illicit Economies and Development
Subjects:
Online Access:https://jied.lse.ac.uk/articles/62
id doaj-916c94adc0a84542b675b1005b26d6c7
record_format Article
spelling doaj-916c94adc0a84542b675b1005b26d6c72021-10-08T13:41:01ZengLSE PressJournal of Illicit Economies and Development2516-72272020-08-012110.31389/jied.6240Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’Katherine Pettus0Independent ConsultantThis paper characterizes the successful civil lawsuits brought by sub-national units of government in the US against multinational pharmaceutical companies to recover the costs of public expenditures (goods and services) incurred as they attempt to manage the ‘opioid crisis,’ as a scapegoating strategy whose function is to deflect attention from the governance failures that allow corporate colonization of the public sphere and rescue the moribund privileges of whiteness enjoyed by the ‘blue collar aristocracy’ until neoliberal globalization rendered them obsolete. Recent drops in white life expectancy, which are associated with chronic diseases and non-medical opioid use, map onto high unemployment and under-employment rates in formerly prosperous communities, now fodder for populist political campaigns. Criminalizing the pharmaceutical companies and executives for peddling prescription medicines to inadequately trained (in the treatment of pain) physicians — some of whom prescribed opioids inappropriately to (majority white) patients/consumers, some of whom developed addictions, and/or poisoning following non-medical use or consumption with alcohol or illicit substances —medicalizes the white opioid crisis and identifies consumers as victims. This distinguishes them from the Americans of color whose ‘drug use’ has been criminalized, who have been disproportionately arrested, and sentenced to long periods of incarceration that entail the loss of civil and political rights, including the right to vote. White elites staked out the ‘color line’ before the Founding, perpetuating it through various scapegoating and ‘shapeshifting’ strategies to the present day. The lawsuits are only the most recent iteration of a morally bankrupt carceral state.https://jied.lse.ac.uk/articles/62opioidsscapegoatingpharmaceutical companieswhitenesscarceralracism
collection DOAJ
language English
format Article
sources DOAJ
author Katherine Pettus
spellingShingle Katherine Pettus
Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
Journal of Illicit Economies and Development
opioids
scapegoating
pharmaceutical companies
whiteness
carceral
racism
author_facet Katherine Pettus
author_sort Katherine Pettus
title Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
title_short Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
title_full Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
title_fullStr Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
title_full_unstemmed Whiteness, Scapegoating, and Scarcity: Medicalizing ‘the US Opioid Crisis’
title_sort whiteness, scapegoating, and scarcity: medicalizing ‘the us opioid crisis’
publisher LSE Press
series Journal of Illicit Economies and Development
issn 2516-7227
publishDate 2020-08-01
description This paper characterizes the successful civil lawsuits brought by sub-national units of government in the US against multinational pharmaceutical companies to recover the costs of public expenditures (goods and services) incurred as they attempt to manage the ‘opioid crisis,’ as a scapegoating strategy whose function is to deflect attention from the governance failures that allow corporate colonization of the public sphere and rescue the moribund privileges of whiteness enjoyed by the ‘blue collar aristocracy’ until neoliberal globalization rendered them obsolete. Recent drops in white life expectancy, which are associated with chronic diseases and non-medical opioid use, map onto high unemployment and under-employment rates in formerly prosperous communities, now fodder for populist political campaigns. Criminalizing the pharmaceutical companies and executives for peddling prescription medicines to inadequately trained (in the treatment of pain) physicians — some of whom prescribed opioids inappropriately to (majority white) patients/consumers, some of whom developed addictions, and/or poisoning following non-medical use or consumption with alcohol or illicit substances —medicalizes the white opioid crisis and identifies consumers as victims. This distinguishes them from the Americans of color whose ‘drug use’ has been criminalized, who have been disproportionately arrested, and sentenced to long periods of incarceration that entail the loss of civil and political rights, including the right to vote. White elites staked out the ‘color line’ before the Founding, perpetuating it through various scapegoating and ‘shapeshifting’ strategies to the present day. The lawsuits are only the most recent iteration of a morally bankrupt carceral state.
topic opioids
scapegoating
pharmaceutical companies
whiteness
carceral
racism
url https://jied.lse.ac.uk/articles/62
work_keys_str_mv AT katherinepettus whitenessscapegoatingandscarcitymedicalizingtheusopioidcrisis
_version_ 1716838287314780160